Biosimilar Reviews Complicated By Improving Analytics, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
With the abundance of data coming in now, FDA must understand structure/function better so it can determine which product attributes matter and which do not, Office of Biotechnology Products Director Steven Kozlowski says.
You may also be interested in...
Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data
Some early meeting requests from potential biosimilar sponsors were not held because they did not include the necessary information for FDA to give development advice.
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.